Lucia BLENDEA, Ancuţa Andreea MILER, Ioan GOTCĂ, Lăcrămioara ATUDOREI, Corina Elena PILAT, Doina SLĂBUŢU, Mihaela ILIE
ABSTRACT :
This systematic literature review examines the clinical efficacy and safety of Ozempic (semaglutide) in the treatment of Type 2 diabetes and weight management, focusing on literature published between 2018 and 2024. The review synthesizes findings from randomized clinical trials (RCTs),
observational studies, and meta-analyses, with particular emphasis on the comparative analyses with other glucagon- like peptide-1 (GLP-1) and receptor agonists. The key outcome measures include glycemic control indicators (HbA1c levels), weight reduction metrics (percent change
from baseline), metabolic parameters (lipid profiles, blood pressure), and adverse event profiles. Statistical significance is evaluated using standard metrics, including p-values, confidence intervals, and hazard ratios, in order to determine the robustness of the findings. The results indicate that
Ozempic leads to significant improvements in glycemic indices, with reductions in HbA1c of approximately 1.5% to 1.8% in many studies, and substantial weight loss, often exceeding 15% of body weight in clinical trials. The safety profile remains manageable, with the most common adverse
events being gastrointestinal in nature. Notably, differences in clinical outcomes relative to other GLP-1 receptor agonists are acknowledged, highlighting the unique benefits of Ozempic. The discussion delves into potential mechanisms driving metabolic benefits and explores the therapeutic
positioning of Ozempic within the contemporary clinical practice. Additionally, the review identifies limitations in the current evidence base and proposes future research directions
in order to enhance the understanding and application of Ozempic in patient care.